New nanoparticle vaccine against chikungunya enters first human tests
NCT ID NCT07394426
First seen Feb 06, 2026 · Last updated Apr 30, 2026 · Updated 9 times
Summary
This early-stage trial tests a new vaccine called PepGNP-ChikV that uses tiny particles to train the immune system against the chikungunya virus. About 40 healthy adults aged 18 to 60 will receive two shots, 42 days apart, and be monitored for safety and immune response for a year. The goal is to see if the vaccine is safe and triggers a strong T-cell response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.